Arylpiperazines having activity at the serotonin 1A receptor

The present invention belongs to the fields of pharmacology and medicinal chemistry, and provides new pharmaceuticals which are useful for the treatment of diseases which are caused or affected by disorders of the serotonin-affected neurological systems, particularly those relating to the 1 receptor. Described herein is a compound of the formula whereinAr′ is a mono or bicyclic aromatic or heteroaromatic radical substituted with one to three substituents selected from the group consisting of hydrogen, (C-C)alkyl, (C-C)alkoxy, (C-C)alkylthio, (C-C)alkenyl, (C-C)alkynyl, (C-C)alkylhalo, (C-C)cycloalkyl, (C-C)cycloalkenyl or halo;Ris hydrogen, (C-C)alkyl, (C-C)alkoxy, (C-C)alkylthio;Ris phenyl, naphthyl or (C-C)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C-C)alkyl, (C-C)alkoxy, (C-C)alkylthio, (C-C)alkenyl, (C-C)alkynyl, (C-C)alkylhalo, (C-C)cycloalkyl, (C-C)cycloalkenyl or halo;Ris selected from the group consisting of hydrogen, (C-C)alkyl, (C-C)alkoxy, (C-C)alkylthio, (C-C)alkenyl, (C-C)alkynyl, (C-C)alkylhalo, (C-C)cycloalkyl, (C-C)cycloalkenyl or halo;X is -(C O)-;or a pharmaceutically acceptable salt racemate, optical isomer or solvate thereof.